Abstract

Domain-aware artificial intelligence has been increasingly adopted in recent years to expedite molecular design in various applications, including drug design and discovery. Recent advances in areas such as physics-informed machine learning and reasoning, software engineering, high-end hardware development, and computing infrastructures are providing opportunities to build scalable and explainable AI molecular discovery systems. This could improve a design hypothesis through feedback analysis, data integration that can provide a basis for the introduction of end-to-end automation for compound discovery and optimization, and enable more intelligent searches of chemical space. Several state-of-the-art ML architectures are predominantly and independently used for predicting the properties of small molecules, their high throughput synthesis, and screening, iteratively identifying and optimizing lead therapeutic candidates. However, such deep learning and ML approaches also raise considerable conceptual, technical, scalability, and end-to-end error quantification challenges, as well as skepticism about the current AI hype to build automated tools. To this end, synergistically and intelligently using these individual components along with robust quantum physics-based molecular representation and data generation tools in a closed-loop holds enormous promise for accelerated therapeutic design to critically analyze the opportunities and challenges for their more widespread application. This article aims to identify the most recent technology and breakthrough achieved by each of the components and discusses how such autonomous AI and ML workflows can be integrated to radically accelerate the protein target or disease model-based probe design that can be iteratively validated experimentally. Taken together, this could significantly reduce the timeline for end-to-end therapeutic discovery and optimization upon the arrival of any novel zoonotic transmission event. Our article serves as a guide for medicinal, computational chemistry and biology, analytical chemistry, and the ML community to practice autonomous molecular design in precision medicine and drug discovery.

Highlights

  • Synthesizing and characterizing small molecules in a laboratory with desired properties is a time-consuming task [1]

  • The workflow for computational autonomous molecular design (CAMD) must be an integrated and closed-loop system (Figure 1) with: (i) efficient data generation and extraction tools, (ii) robust data representation techniques, (iii) physics-informed predictive machine learning models, and (iv) tools to generate new molecules using the knowledge learned from steps i–iii

  • Such an automated pipeline will accelerate the hit identification and lead optimization for the desired therapeutic candidates but can actively be used for machine reasoning to develop transparent and interpretable ML models. These workflows, in principle, can be combined intelligently with experimental setups for computer-aided synthesis or screening planning that includes synthesis and characterization tools, which are expensive to explore in the desired chemical space

Read more

Summary

Introduction

Synthesizing and characterizing small molecules in a laboratory with desired properties is a time-consuming task [1]. The experimental process involves a series of steps, each requiring several correlated parameters that need to be tuned [2,3], which is a daunting task, as each parameter set conventionally demands individual experiments This has slowed down the discovery of high-impact small molecules and/or materials, in some case by decades, with possible implications for diverse fields, such as in energy storage, electronics, catalysis, drug discovery, etc. Larger portions of the chemical space are still uncovered, and it is expected to contain exotic materials with the potential to bring unprecedented advances to state-of-the-art technologies Exploring such a large space with conventional experiments will take time and a lot of resources [4,5,6,7].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call